Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

Clinical trial NCT00314951 · COMPLETED

Trial details

NCT number: NCT00314951
Sponsor: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Clostridium Infections Diarrhea

Start date: 2006-05-02
Primary completion: 2008-07-23
Enrollment: 629

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.